105 related articles for article (PubMed ID: 21789688)
41. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
[TBL] [Abstract][Full Text] [Related]
42. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
43. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.
Zhang XM; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Zhou LQ; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1051-6. PubMed ID: 23021436
[TBL] [Abstract][Full Text] [Related]
44. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.
Fabbri A; Lenoci M; Gozzetti A; Marotta G; Raspadori D; Forconi F; Lauria F
Hematol J; 2004; 5(6):472-4. PubMed ID: 15570287
[TBL] [Abstract][Full Text] [Related]
45. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
[TBL] [Abstract][Full Text] [Related]
46. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
47. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
[TBL] [Abstract][Full Text] [Related]
48. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
[TBL] [Abstract][Full Text] [Related]
49. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Leblond V; Lévy V; Maloisel F; Cazin B; Fermand JP; Harousseau JL; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O;
Blood; 2001 Nov; 98(9):2640-4. PubMed ID: 11675332
[TBL] [Abstract][Full Text] [Related]
50. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
[TBL] [Abstract][Full Text] [Related]
51. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Bishton MJ; Rule S; Wilson W; Turner D; Patmore R; Clifton-Hadley L; McMillan A; Lush R; Haynes A
Br J Haematol; 2020 Aug; 190(4):545-554. PubMed ID: 32150649
[TBL] [Abstract][Full Text] [Related]
52. Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
Yung L; Cunningham D; Hancock B; Smith P; Maclennan K; Linch D; McMillan A
Br J Cancer; 2004 Aug; 91(4):695-8. PubMed ID: 15280929
[TBL] [Abstract][Full Text] [Related]
53. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
Tse E; Chan JC; Pang A; Au WY; Leung AY; Lam CC; Kwong YL
Leukemia; 2007 Oct; 21(10):2225-6. PubMed ID: 17525720
[No Abstract] [Full Text] [Related]
54. All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.
Cox MC; Banchi M; Pelliccia S; Di Napoli A; Marcheselli L; Patti C; Anticoli Borza P; Battistini R; Di Gregorio F; Orlandi P; Bocci G
Cancer Chemother Pharmacol; 2020 Dec; 86(6):841-846. PubMed ID: 33070248
[TBL] [Abstract][Full Text] [Related]
55. Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.
Salamoon M; Bachour M; Hussein T; Kenj M
Med Oncol; 2013 Jun; 30(2):554. PubMed ID: 23550277
[TBL] [Abstract][Full Text] [Related]
56. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Carson KR; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta MA; Shustov AR; Advani RH; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Cancer; 2017 Apr; 123(7):1174-1183. PubMed ID: 27911989
[TBL] [Abstract][Full Text] [Related]
57. PTCL therapies: a review of treatment and outline of novel therapies.
Khan N; Cheson BD
Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
[TBL] [Abstract][Full Text] [Related]
58. Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK).
Jo JC; Choi Y; Shin HJ; Yhim SN; Lee HS; Lee WS; Lee JH; Kim H; Oh SY
Ann Hematol; 2016 Mar; 95(4):619-24. PubMed ID: 26779714
[TBL] [Abstract][Full Text] [Related]
59. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
[TBL] [Abstract][Full Text] [Related]
60. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
Zinzani PL; Pellegrini C; Broccoli A; Stefoni V; Gandolfi L; Quirini F; Argnani L; Berti E; Derenzini E; Pileri S; Baccarani M
Leuk Lymphoma; 2011 Aug; 52(8):1585-8. PubMed ID: 21504290
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
